FSD Pharma’s Investments in Cutting-Edge Tech Could Pay Big Dividends
Ryan Allway
February 26th, 2019
Exclusive, News, Top Story
Many cannabis companies have predictable business models—they grow and sell cannabis flower or perhaps extract them into edibles or vape pens. While most companies are focused on maximizing their production footprint, some companies have placed an additional focus on research and development. These investments could pay big dividends in the future if they prove to be breakthroughs in cannabis cultivation or delivery.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) has become well-known for its massive cannabis cultivation facility that’s being built in a former Kraft plant in Cobourg, Ontario, but investors should also take note of its investment in cutting-edge research and development, including delivery systems and cultivation techniques.
New Delivery Methods
The medical cannabis market could reach $55 billion by 2024, according to Global Market Insights, driven by growing demand to treat chronic pain caused by neurological disorders, cancer, HIV/AIDS, and arthritis. In addition, the increasing preference of cannabis over opioids could add significantly more upside over the coming years. The key is developing effective delivery systems for various target indications.
FSD Pharma recently announced a $1.5 million strategic investment in and profit-sharing agreement with Pharmastrip Corp., developer of medical cannabis-infused oral thin film strips. Under the terms of the agreement, FSD will install Pharmastrip’s proprietary equiment at its Cobourg, Ontario facility and use the equipment to manufacture oral thin film strips and Pharmastrip will grant FSD an exclusive license to manufacture and sell in Canada.
“FSD made this strategic investment because of the potential we see in alternative delivery methods for cannabis, such as Pharmastrip’s oral thin film strips,” said FSD Pharma Founder and President Zeeshan Saeed. “We expect the demand for alternative delivery methods for cannabis for both THC and CBD to increase as the market continues to develop. [We] look forward to beginning production once the necessary license has been granted.”
New Production Methods
Thousands of acres of cannabis are harvested each year across North America. With the legalization of medical and adult-use cannabis in Canada and certain U.S. states, these figures are poised to significantly expand over the coming years. The problem is that growing and harvesting cannabis plants is an energy intensive and expensive process—a process that some companies are hoping to short-circuit with new techniques.
FSD Pharma recently announced a non-binding letter of intent with Solarvest BioEnergy Inc. (TSX-V: SVS) to research the use of algal expression technology in developing pharmaceutical-grade cannabinoids. The company is already using algae to create omega-3 products for the nutraceutical industry, and the same approach could be used to develop cannabinoids in a much faster and more reliable process.
“If successful, this could dramatically disrupt current cannabis cultivation methods for medical purposes,” said FSD Pharma President Zeeshan Saeed. “It could reduce the majority of time, space, and costs associated with cannabis cultivation for medical purposes, specifically cannabis with GMP Certification. We are very pleased to collaborate with Solarvest on the development of promising alternative methods of cannabinoid production.”
Looking Ahead
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) continues to invest heavily in cutting-edge technologies that could revolutionize the way cannabis is grown and consumed. At the same time, the company continues to make progress in building its massive cannabis cultivation facility in Cobourg, Ontario, which could make it one of the largest licensed producers in Canada at full production.
On February 19, the company announced that it received a Standard Processing License from Health Canada. The license enables the facility to begin packaging cannabis for inspection by Health Canada and is a prerequisite to applying for a pre-sale inspection, which management expects will be scheduled very soon. The next steps are receiving the final sales license and beginning production at the facility.
For more information, visit the company’s website at www.fsdpharma.com.
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Harvest One is a global cannabis company that develops and provides innovative lifestyle and wellness products to consumers and patients in regulated markets around the world.
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
